financetom
Business
financetom
/
Business
/
Update: Crocs Shares Fall After Issuing Lower-Than-Expected Q4 Adjusted EPS Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Crocs Shares Fall After Issuing Lower-Than-Expected Q4 Adjusted EPS Guidance
Nov 3, 2024 1:57 PM

10:56 AM EDT, 10/29/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and first paragraph.)

Crocs ( CROX ) shares fell over 17% in recent Tuesday trading after it issued a lower-than-expected Q4 adjusted earnings outlook.

The company reported Q3 adjusted earnings of $3.60 per diluted share, up from $3.25 a year earlier.

Analysts polled by Capital IQ expected $3.11.

Revenue for the quarter ended Sept. 30 was $1.06 billion, up from $1.05 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.05 billion.

For Q4, Crocs ( CROX ) expects adjusted earnings of $2.20 to $2.28 per diluted share. Analysts polled by Capital IQ expect $2.73.

The footwear company said it now expects adjusted earnings of $12.82 to $12.90 per diluted share in 2024, compared with its earlier guidance of $12.45 to $12.90. Analysts surveyed by Capital IQ expect $12.85.

Price: 114.38, Change: -23.67, Percent Change: -17.15

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck's Welireg Recommended for Conditional Approval by European Medicines Agency
Merck's Welireg Recommended for Conditional Approval by European Medicines Agency
Dec 13, 2024
08:05 AM EST, 12/13/2024 (MT Newswires) -- Merck ( MRK ) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended conditional approval of its experimental drug, Welireg, to treat certain adult patients with von Hippel-Lindau disease-associated Tumors and certain patients with advanced renal cell carcinoma. The company said it also recommended for adult patients...
Goldman Sachs granted licence for China fund sales
Goldman Sachs granted licence for China fund sales
Dec 13, 2024
HONG KONG (Reuters) - Goldman Sachs ( GS ) received regulatory approval to sell funds in China, the latest U.S. investment bank to get a financial licence in a sign of Beijing's commitment to continue opening up the sector to foreign companies. The Beijing Bureau of China Securities Regulatory Commission (CSRC) granted a fund sales licence to the U.S. bank's...
Goldman Sachs granted licence for China fund sales
Goldman Sachs granted licence for China fund sales
Dec 13, 2024
HONG KONG, Dec 13 (Reuters) - Goldman Sachs ( GS ) received regulatory approval to sell funds in China, the latest U.S. investment bank to get a financial licence in a sign of Beijing's commitment to continue opening up the sector to foreign companies. The Beijing Bureau of China Securities Regulatory Commission (CSRC) granted a fund sales licence to the...
TerraVest Q4 Profit Falls on Depreciation Expenses, Hikes Dividend 17%
TerraVest Q4 Profit Falls on Depreciation Expenses, Hikes Dividend 17%
Dec 13, 2024
08:04 AM EST, 12/13/2024 (MT Newswires) -- TerraVest Industries ( TRRVF ) on Friday said fourth-quarter net income fell due to depreciation expenses, while revenue rose. The company also boosted its dividend by 17%. Net income fell to $13.8 million, or $0.59 per diluted share, from $15.5 million, or $0.73 per diluted share. The decrease is mainly due to depreciation...
Copyright 2023-2026 - www.financetom.com All Rights Reserved